Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673202 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL17841947 | 0.83 | ALDH1A1 (0.48) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL13099488 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL19936530 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL6585676 | 0.79 | ALDH1A1 (0.54) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL2321958 | 0.79 | — | — | |
| SCHEMBL27830172 | 0.79 | ALDH1A1 (0.45) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL15567525 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL11487878 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TRPA1GAAMGAMSI | |
| SCHEMBL328925 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2935284-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | AbbVie Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-1189895-B8 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1189895-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-06-08 | — | — | EP | disclosed |
| CN-1164579-C | Thiazole and oxazole derivatives and their pharmaceutical use | — | 2004-09-01 | — | — | CN | disclosed |
| US-6723740-B2 | ADMINISTERING THERAPEUTIC AMOUNT OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST TO LOWER TRIGLYCERIDES | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6710063-B1 | Activators of PPAR delta | SMITHKLINE BEECHAM CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | CHAO ESTHER YU-HSUAN (US) | 2003-10-30 | — | — | US | disclosed |
| CN-1358179-A | Thiazole and oxazole derivatives and their pharmaceutical use | GLAXO GROUP LTD (GB) | 2002-07-10 | — | — | CN | disclosed |
| EP-1189895-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001000603-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2001-01-04 | — | — | WO | disclosed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | ALDH1A1 801/4885TRPA1 535/4885GAA 4442/4885 |
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | PPARA, PPARD, PPARG | ALDH1A1 839/4885TRPA1 2942/4885GAA 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.